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There are an estimated 18 million Alzheimer’s disease (AD) sufferers worldwide and
with no disease modifying treatment currently available, development of new therapies
represents an enormous unmet clinical need. AD is characterized by episodic memory
loss followed by severe cognitive decline and is associated with many neuropathological
changes. AD is characterized by deposits of amyloid beta (Aβ), neurofibrillary tangles,
and neuroinflammation. Active immunization or passive immunization against Aβ leads
to the clearance of deposits in transgenic mice expressing human Aβ. This clearance
is associated with reversal of associated cognitive deficits, but these results have not
translated to humans, with both active and passive immunotherapy failing to improve
memory loss. One explanation for these observations is that certain anti-Aβ antibodies
mediate damage to the cerebral vasculature limiting the top dose and potentially reducing
efficacy. Fc gamma receptors (FcγR) are a family of immunoglobulin-like receptors which
bind to the Fc portion of IgG, and mediate the response of effector cells to immune
complexes. Data from both mouse and human studies suggest that cross-linking FcγR
by therapeutic antibodies and the subsequent pro-inflammatory response mediates the
vascular side effects seen following immunotherapy. Increasing evidence is emerging
that FcγR expression on CNS resident cells, including microglia and neurons, is
increased during aging and functionally involved in the pathogenesis of age-related
neurodegenerative diseases. Therefore, we propose that increased expression and ligation
of FcγR in the CNS, either by endogenous IgG or therapeutic antibodies, has the potential
to induce vascular damage and exacerbate neurodegeneration. To produce safe and
effective immunotherapies for AD and other neurodegenerative diseases it will be vital
to understand the role of FcγR in the healthy and diseased brain. Here we review
the literature on FcγR expression, function and proposed roles in multiple age-related
neurological diseases. Lessons can be learnt from therapeutic antibodies used for the
treatment of cancer where antibodies have been engineered for optimal efficacy.
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INTRODUCTION
Alzheimer’s disease (AD) is a devastating illness with a hugely
detrimental effect on the quality of life of patients and their
families. An estimated 18 million people worldwide suffer from
AD and with an ever ageing population; the number of cases
will increase. The currently approved treatments for AD are:
inhibitors of the enzyme acetyl-cholinesterase, and Memantine
which is a blocker of the neurotransmitter channel for glu-
tamate (NMDA). Both these therapies are able to transiently
improve cognition (Reisberg et al., 2003; Tariot et al., 2004),
but no treatment is available that can modify disease pro-
gression. The increasing number of individuals suffering from
AD and the burden placed on our healthcare services, makes
developing effective AD therapeutics an urgent unmet clinical
need.
AD patients initially present with episodic memory loss which
is followed by severe cognitive decline, but pathological changes
begin decades before clinical symptoms arise. The disease is char-
acterized by a number of neuropathological changes including:
the deposition of misfolded proteins in the brain as extra-cellular
plaques and intracellular tangles, loss of synapses and neurons
and an increased number and activation of glial cells. The pri-
mary component of plaques was identified as amyloid beta (Aβ),
a 39–43 amino acid peptide cleaved from the amyloid precursor
protein (APP) (Masters et al., 1985; Allsop et al., 1988). Later it
was discovered that mutations in the APP gene (Goate et al., 1991;
Mullan et al., 1992), or increased copy number of APP found in
Down’s syndrome are associated with early onset AD pathology
(Olson and Shaw, 1969). These histological and genetic findings
formed the basis of the amyloid cascade hypothesis, which states
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that increased production or accumulation of Aβ underlies the
pathology of AD (Hardy and Selkoe, 2002). This hypothesis has
driven most AD research in the last 20 years, resulting in the
development of therapies targeted to reduce Aβ production or
clear Aβ deposits from the brain.
Immunotherapy is one strategy that has been developed to
clear Aβ from the brains of AD patients, with a number of
vaccines and monoclonal antibodies against Aβ that have been
tested in clinical trials. Despite early optimism from successful
pre-clinical work, this approach has not translated into disease
modifying therapies. In 2012 two phase III clinical trials for
anti-Aβ antibodies Bapineuzumab (AAB-001, ELN115727) and
Solanezumab (EXPEDITION 1 and EXPEDITION 2) failed to
meet primary clinical endpoints of improvement in cognition
(Doody et al., 2014; Salloway et al., 2014). A major safety finding
was that Bapineuzumab caused vascular side effects designated
amyloid related imaging abnormalities (ARIAs). This led to the
discontinuation of the 2mg/kg dose, which may have decreased
efficacy (Salloway et al., 2010). In spite of these disappointing
clinical results interest in this form of therapy persists with sec-
ond generation antibodies that are currently being tested in AD
prevention trials.
The mechanism underlying the development of side effects is
poorly understood, and only a limited number of studies have
investigate if the effector function of the therapeutic antibodies
is critical for efficacy. Fc gamma receptors (FcγRs) bind to the
constant domain of IgG, and are expressed on a wide variety of
cell types including CNS macrophages- microglia. Activation of
FcγR can result in a pro-inflammatory response including the
release of cytokines and other mediators (Carbone et al., 2013).
Experimental models of AD and observations from clinical trials
have provided evidence that activating FcγRs may be responsi-
ble for the activation of microglia following immunotherapy, and
the associated side effects (Wilcock et al., 2006; Adolfsson et al.,
2012; Freeman et al., 2012). There are a number of inflammatory
changes within the CNS during ageing, which are further affected
by AD, including increased expression of all FcγRs on microglial
cells and/or perivascular macrophages (Peress et al., 1993; Cribbs
et al., 2012). This is functionally relevant as increased expres-
sion of activating FcγRs on microglia could drive an exacerbated
response to therapeutic antibodies, possibly explaining the side
effects observed in the Bapineuzumab clinical trials.
This review will describe the emerging roles for specific FcγRs
in the underlying pathology of neurodegeneration and the poten-
tial for FcγR mediated tissue damage in the CNS. This will be
discussed in the context of immunotherapy for AD and the con-
siderations that should be made before the development of next
generation antibodies targeting CNS antigens.
FC RECEPTORS
FcγRs bind to the constant region of IgG and are expressed on
the surface of a wide range of immune effector cells. Human
FcγRs can be functionally divided into three classes: activating
(FcγRI, FcγRIIa, FcγRIIc, and FcγRIIIa), inhibitory (FcγRIIb) or
gpi linked decoy (FcγRIIIb). There are a number of subclasses
of human IgG (IgG1, IgG2, IgG3, and IgG4), each with vary-
ing affinity for the different FcγRs (Bruhns et al., 2009). There
are four known murine FcγRs: activating (FcγRI, FcγRIII, and
FcγRIV) and inhibitory (FcγRIIb) (Nimmerjahn and Ravetch,
2008). Similar to humans mice have 4 IgG subclasses (IgG1,
IgG2a, IgG2b, and IgG3), but it should be noted that the nomen-
clature is different between species, and therefore human IgG1
is not homologous to murine IgG1, and its effector function is
instead more similar to murine IgG2a.
Activating Fc receptors (with the exception of human FcγRIIa)
are associated with and signal through a separate Fc gamma
chain (Fcγ chain) which contains immune-tyrosine activation
motifs (ITAMs). A common model used to study the roles of
activating FcγRs in vivo are mice deficient for this Fcγ chain,
who lack expression of functional activating FcγRs. Activating
FcγR deficient mice show: decreased antibody mediated phago-
cytosis, abnormal platelet activation and an attenuate immune
response to immune complexes (Takai et al., 1994). However,
some of these effects may be mediated by other immune recep-
tors, such as c-type lectins, which also depend on Fcγ chain
signaling (Geijtenbeek and Gringhuis, 2009). In contrast to acti-
vating Fcγ receptors, the expression and therefore function of the
inhibitory Fcγ receptor (FcγRIIb) is maintained. Human FcγRIIa
carries an intrinsic ITAM in its cytoplasmic domain. Ligation
of IgG-immune complexes by activating FcγRs results in the
crosslinking of the receptor and the phosphorylation of ITAMs
in the cytoplasmic chain. This forms a binding site for the Spleen
tyrosine kinase (Syk), which then activates downstream signal-
ing cascades such as the PI3K pathway. Cellular calcium levels are
increased and the cell becomes activated which can result in: pro-
liferation, cytokine/chemokine release, phagocytosis and antigen
presentation (Nimmerjahn and Ravetch, 2008). The inhibitory
FcγRIIb signals through an intrinsic cytoplasmic immuno tyro-
sine inhibitory motif (ITIM), cross-linking with an activating
receptor results in ITIM phosphorylation leading to the inhibi-
tion of cellular activation (Nimmerjahn and Ravetch, 2008). The
process of FcγR mediated activation or inhibition of an effector
cell is outlined in Figure 1.
The functional consequences of FcγR ligation depends on the
ratio of activating to inhibitory FcγRs expressed on the effec-
tor cell. Cells that have a high ratio of activating to inhibitory
FcγRs are more prone to an uncontrolled immune response;
this is demonstrated by FcγRIIb−/− mice which have an exacer-
bated response to autoantibodies inducing more tissue damage
(Clynes et al., 1999; Yuasa et al., 1999). The response is also
determined by the subclass; for example human IgG1 has higher
affinity for activating FcγRs as compared to human IgG4, and
will induce a more pro-inflammatory response (Bruhns et al.,
2009). Activation of macrophages, including microglia, through
FcγRs results in phagocytosis and polarization to an M2b pheno-
type which has attributes of both M1 and M2 macrophages. M2b
macrophages release high levels of pro inflammatory cytokines
such as TNFα and IL-1β as well as nitric oxide, all having potent
tissue damaging properties (Mosser, 2003; Mantovani et al., 2004;
Mosser and Edwards, 2008). In the context of immunother-
apy anti-Aβ antibodies reaching the CNS will bind to and coat
plaques; this promotes activation of microglia through FcγRs,
resulting in the phagocytosis of the antibody-coated plaques and
release of pro-inflammatory mediators. It should be noted that
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FIGURE 1 | Activation or inhibition of a cell by Fc receptor ligation of IgG
immune complexes. (A) Cross linking of activating FcγRs by IgG immune
complexes results in the phosphorylation of cytoplasmic ITAM motifs. This
allows the recruitment of SH2 domain containing kinases of the SYK family.
These kinases activate pathways such as the RAS and PI3K pathways
resulting in increased cellular calcium and activation of the cell. (B) The cross
linking of an inhibitory receptor to an activating receptor results in the
phosphorylation of an ITIM, leading to the recruitment of the phosphatase
SHIP1. SHIP1 removes the 5’phopshate from PiP345 inhibiting downstream
PI3K signaling, and also interacts with other adaptor proteins to inhibit other
pathways. (C) Aβ binds with high affinity to the inhibitory FcγRIIb
(KD = 5.67 × 10−8 M). Through an unknown signaling pathway, the ligation of
Aβ causes the loss of FcγRIIb expressing neurons. (D) FcγRI possesses an
extra immunoglobulin like domain compared to other FcγRs. This allows the
high affinity binding of monomeric IgG, ligation of monomeric IgG by FcγRI
expressing neurons, facilitating antibody uptake.
studies in FcγR deficient mice and application of antibodies with
reduced or no effector function have shown that there are mech-
anisms of plaque removal independent of FcγR binding (Bacskai
et al., 2002; Das et al., 2003; Wilcock et al., 2006).
HUMORAL IMMUNITY IN THE CNS
FcγR expression on CNS cells
Although macrophages and microglia have been implicated as
effector cells in the CNS following immunotherapy, recent data
suggest a more broad expression pattern of FcRs in the CNS.
Increasing evidence suggest that multiple cell types within the
CNS express FcγRs, and changes in expression patterns occur in
response to different stimuli. Tables 1, 2 summarize the expres-
sion pattern and function of FcγRs on CNS cells in humans and
mice respectively, under healthy and diseased conditions.
Human microglia express: FcγRI, FcγRIIa, FcγRIIb, and
FcγRIIIa albeit at very low levels under normal conditions. The
expression is increased on microglia in the CNS of patients with
MS (Ulvestad et al., 1994), and a number of neurodegenerative
conditions. In AD ramified microglia in the parenchyma, but
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Table 1 | Expression of FcγRs on murine CNS cells.
Cell type FcγRs
expressed
Conditions for
expression
References
Microglia FcγRI,
FcγRIIb,
FcγRIII, and
FcγRIV
All↑: Neurodegeneration
± systemic LPS,
immune complex
formation in retina
FcγRII/III↑: Amyloid beta
immunotherapy or
arthus reaction in the
brain
FcγRI↑: ageing,
especially in white
matter regions
Wilcock et al.,
2004b; Lunnon
et al., 2011; Hart
et al., 2012;
Teeling et al.,
2012; Murinello
et al., 2014
Neurons FcγRIIb,
FcγRIV
FcγRII/III
FcγRIIb↑: Aβ treatment
FcγRIV↑: APOE−/−
genetic background
Kam et al., 2013
Fernandez-
Vizarra et al.,
2012
Astrocytes FcγRI FcγRI↑: increased CNS
IgG
Li et al., 2008
Oligo-
dendrocytes
Fcγ chain Fcγ chain is expressed
by oligodendrocyte
precursor cells
Nakahara et al.,
2003
Endothelial
cells
FcRn FcRn constitutively
expressed on CNS
endothelium
Deane et al.,
2005
This table shows the expression patterns of FcγRs on different murine CNS cell
types. The conditions in which up or down regulation of specific FcγRs has been
observed have been recorded.
especially those associated with plaques express higher levels
of: FcγRI, FcγRII, and FcγRIII compared to age matched con-
trols (Peress et al., 1993). Interestingly the expression of FcγRI
and FcγRIIb are decreased on microglia of AD patients whose
plaques were cleared by active immunotherapy (Zotova et al.,
2013). Age related macular degeneration is associated with an
increased number of CD45+ leukocytes expressing activating
FcγRIIa (and to a lesser extent inhibitory FcγRIIb) at the choroid-
retinal epithelial cell interface (Murinello et al., 2014). Finally
increased FcγRI microglial expression is found in the CNS of
patients with Parkinson’s Disease (Orr et al., 2005). Murine
microglia express all known FcγRs: FcγRI, FcγRIIb, FcγRIII, and
FcγRIV. The expression of these receptors is increased in response
to a number of different insults to the CNS. All four FcγRs are up
regulated on microglia in response to experimental induced neu-
rodegeneration (prion disease) and further upregulated by sys-
temic inflammation, whilst up-regulation of FcγRII/III has been
observed in TG2576 APP mice (Wilcock et al., 2004b; Lunnon
et al., 2011). We showed that type III hypersensitivity (or Arthus
reaction) in the CNS (brain and retina) induces robust expression
of: FcγRI, FcγRIIb, FcγRIII, and FcγRIV on microglia followed
by a robust neuro-inflammatory response (Teeling et al., 2012;
Murinello et al., 2014). Normal ageing is also associated with
increased FcγR immuno-reactivity, andmicroglia especially those
Table 2 | Expression of FcγRs on human CNS cells.
Cell type FcRs
expressed
Conditions for expression References
Microglia FcγRI,
FcγRIIa,
FcγRIIb,
FcγRIIIa
All↑ Alzheimer’s disease,
multiple sclerosis
FcγRI↑ Parkinson’s disease
FcγRI and FcγRIIb↑
Alzheimer’s disease after
plaque clearance
FcγRIIa and FcγRIIb↑ Age
related macular degeneration
Peress et al.,
1993; Ulvestad
et al., 1994; Orr
et al., 2005;
Zotova et al.,
2013; Murinello
et al., 2014
Neurons FcγRI,
FcγRIIb
FcRI Expressed constitutively
on sensory and motor
neurons
FcRIIb↑ Alzheimer’s disease
Mohamed et al.,
2002; Andoh and
Kuraishi, 2004
Kam et al., 2013
This table shows the expression patterns of FcγRs on different human CNS cell
types. The conditions in which up or down regulation of specific FcγRs has been
observed have been recorded. There are a limited number of studies examining
FcγR expression for most human CNS cell types.
in white matter regions of the CNS, show elevated expression of
FcγRI (Hart et al., 2012).
The expression of FcγRs on neurons was once controversial,
however a number of studies have now documented their expres-
sion on neurons both in vitro and in vivo. Human sensory and
motor neurons express the high affinity FcγRI which enable the
cells to take up IgG from the surroundings (Mohamed et al.,
2002; Andoh and Kuraishi, 2004). The inhibitory FcγRIIb has
been detected on healthy neurons in the hippocampus of both
mice and humans. The expression of FcγRIIb is increased on neu-
rons in the AD brain, and also in response to treatment with
Aβ (Nakamura et al., 2007; Kam et al., 2013). Murine neurons
have been found to express FcγRII/III which mediate the uptake
of therapeutic anti tau antibodies into neurons (Congdon et al.,
2013). Finally neurons in the hippocampus of APOE−/− mice
express FcγRIV and signal in response to the higher levels of IgG
in the CNS (Fernandez-Vizarra et al., 2012).
There are a limited number of studies investigating FcγR
expression on other CNS cell types. FcγRI has been detected on
astrocytes cultured in vitro, and also on rat astrocytes in vivo in
response to BBB permeability changes (Li et al., 2008). There is
also evidence that the Fcγ chain is required for differentiation of
oligodendrocytes, however with other immunoreceptors that also
signal through the Fcγ chain it is not possible to conclude that
FcγRs are required (Nakahara et al., 2003). Finally, murine CNS
endothelial cells express the neonatal Fc receptor (FcRn). FcRn
has been found to mediate the transport of therapeutic anti-Aβ
antibodies from the CNS into the periphery (Deane et al., 2005).
Immunoglobulin G entry into the CNS
Despite tight control by the BBB, it is apparent that small amounts
of IgG enter the healthy brain and it has been estimated that
0.1% of circulating IgG enters the CNS via passive diffusion
(Poduslo et al., 1994). However, this may be altered during age-
ing and/or disease, and associated changes in BBB integrity and
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interaction with FcRn. For example, under healthy conditions,
IgG is removed from the CNS by an efficient process of reverse
transcytosis across the BBB (Zhang and Pardridge, 2001), medi-
ated by the neonatal transport receptor, FcRn (Schlachetzki et al.,
2002; Deane et al., 2005).This transport of IgG is saturated at high
levels of IgG, reducing the rate of IgG efflux. It is widely recog-
nized that a functional blood-brain-barrier (BBB) limits passage
of macromolecules and cells from the periphery and that disrup-
tion of the BBB by insults such as, ageing, stress and systemic
inflammation, obesity is associated with an influx of serum pro-
teins, including IgG (Lu et al., 2001; Diamond et al., 2006).Under
these conditions the net influx of IgG would be increased, result-
ing in accumulation of IgG in the parenchyma, and around
cerebral vessels.
NEW ROLES FOR FCγRS IN NEURODEGENERATION
There are emerging roles for different FcγRs in the underly-
ing pathology of neurodegenerative disorders. As outlined in
the previous section, increased expression of all FcγRs is con-
sistently reported in human brain tissue of neuro-inflammatory
and degenerative diseases including: Parkinson’s (PD), AD, and
Multiple sclerosis (Nyland et al., 1984; Peress et al., 1993; Ulvestad
et al., 1994; Orr et al., 2005; Cribbs et al., 2012). There is evidence
that ligation of specific FcγRs in the CNS by IgG and alter-
nate ligands can promote neuroinflammation and/or enhance
neurodegeneration.
Auto antibodies
Apart from elevated FcγR, increased levels of total IgG in the CNS
has also been reported in various neurodegenerative diseases, pos-
sibly as a result of an age-related increase in BBB permeability
(Bouras et al., 2005). Serum from AD and PD patients are known
to contain auto-antibodies to glutamatergic and dopaminergic
neurons, which are selectively affected in AD and PD patients
respectively. Furthermore, neurons of the substantia nigra (SN)
from patients with Idiopathic cases of PD have been found to be
immuno-reactive for IgG (Orr et al., 2005). IgG isolated from the
sera of PD patients, injected into the brains of mice, specifically
binds neurons in the SN. This binding induces neuroinflamma-
tion as measured by increased expression of CD11b, and loss of
SN neurons (He et al., 2002). The use of Fcγ chain −/− mice,
which lack all activating FcγRs or F(ab’)2 fragments of PD IgG
prevented these responses (He et al., 2002), demonstrating that
an FcγR mediated mechanism could drive neurodegeneration in
PD. A similar role for FcγRs in the pathology of AD is described.
Increased expression of FcγRs (FcγRI, FcγRII, and FcγRIIIa) in
disease affected areas of AD patients has been observed on both
glial cells and neurons (Peress et al., 1993; Bouras et al., 2005).
Application of serum-derived IgG from AD patients, contain-
ing neuron specific antibodies, into the forebrain of rats results
in the selective reduction of cholinergic neurons, supporting the
concept that in AD auto-reactive antibodies could in part drive
neuronal loss (Engelhardt et al., 2000). The histological examina-
tion of brain tissue from AD patients provides further evidence
for a detrimental role of these antibodies, as cholinergic neurons
that stain positive for IgG also express markers of degeneration
such as caspase 3 (D’Andrea, 2003).
Neuronal FcγRs
Evidence for a detrimental role of increased influx of serum
derived IgG into the CNS was recently shown in ApoE defi-
cient mice. This model is of interest to AD researchers because
the ApoE4 allele is the largest genetic risk factor for sporadic
AD (Strittmatter and Roses, 1995). ApoE deficient mice develop
many neuropathological changes in common with AD includ-
ing: increased blood brain barrier permeability, accumulation
of intra neuronal Aβ, hyper phosphorylation of Tau and cog-
nitive impairment (Fernandez-Vizarra et al., 2012). A critical
role for FcyR was elegantly shown in this experimental model.
When crossed onto Fcγ chain deficient mice the double knock
out animals have similar increased BBB permeability. However,
they are protected from other neuropathological changes includ-
ing: microgliosis, neuronal damage and cognitive impairment.
Fcγ chain deficient mice also do not express other immune
receptors such as mincle or dectin 2(Geijtenbeek and Gringhuis,
2009), so this should be taken into account when analyzing
this data. However specific knock-down of FcγRIV with siRNA
prevents similar effects of IgG on primary neurons in vitro.
These results imply that it is the interaction between IgG in the
brain and FcγR expressing neurons that drive AD-like pathol-
ogy in these mice. Neurons of AD patients and APP transgenic
mice also express the inhibitory receptor FcγRIIb (Kam et al.,
2013). FcγRIIb has a low affinity for monomeric IgG1 (KD =
9.43 × 10−6 M), but binds with high affinity to Aβ (KD = 5.67 ×
10−8 M). Aβ is a potent inducer of neuronal apoptosis, and
this effect is ameliorated in FcγRIIb deficient neurons (Kam
et al., 2013). It is not currently known if Aβ signals through
FcγRIIb using the same signaling pathway as immune com-
plexes. It will be important to understand if cross-linking of
neuronal FcγRIIb by immune complexes can induce the same
effect.
Protection from neurodegeneration in Fcγ chain −/− mice
Our own studies have provided evidence that the Fcγ chain
also contributes to IgG-mediated inflammation and neuronal
function. Formation of IgG immune complexes in the mouse
brain (Teeling et al., 2012) or the mouse and human retina
results in a transient, but robust neuroinflammatory response,
that depends on activating FcγRs (Murinello et al., 2014).
Further, using an experimental model of neurodegeneration,
we show that FcγRs are expressed on microglia and fur-
ther up-regulated following systemic inflammation. The latter
is associated with increased production of pro-inflammatory
cytokines, which is attenuated in Fcγ chain deficient mice
(Lunnon et al., 2011). The Fcγ chain deficient background
is also neuroprotective in other experimental models of
neurodegenerative disease, including: ischemic stroke (Komine-
Kobayashi et al., 2004) and synuclein-induced neurodegeneration
following AAV transfer (Cao et al., 2010, 2012). These results
indicate that the Fcγ chain is involved in neurodegenera-
tion, however due to the loss of other immune receptors
which signal through the Fcγ chain it is currently not pos-
sible to conclude that only FcγRs are involved and further
research using models for to test the role for specific FcγR is
required.
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The effects of soluble inflammatory mediators
The ligation of therapeutic antibody coated plaques or auto-
antibody coated neurons by activating FcγRs may lead to the
polarization of macrophages to a M2b phenotype and the pro-
duction of a number of cytokines, chemokines, and inflammatory
mediators. Receptors for a number of cytokines are expressed on
CNS resident cells, so what is the effect of increasing the levels of
these mediators on neurons?
Neuronal function is tightly regulated and a small change
in homeostasis can be detrimental depending on the levels of
cytokines produced. At physiological levels TNFα has impor-
tant roles in regulating normal brain activity including regulation
of synaptic scaling (Stellwagen and Malenka, 2006). Low lev-
els of monomeric IgG in the brain (0.2-20 ug/ml) are observed
under healthy conditions and induce low levels of TNFα via
tonic signaling of FcγRI expressed on microglia. Under these
condition TNFα is neuroprotective against excitotoxicity, but
increasing levels of monomeric IgG abrogates this effect even-
tually becoming neurotoxic (Hulse et al., 2008). At higher levels
TNFα, at least in vitro, is neurotoxic causing loss of cells by sig-
naling through TNFR1 (Yang et al., 2002). Therefore increased
TNFα production as a result of excessive FcγR ligation could be
twofold: high levels could induce apoptosis of susceptible neu-
rons or it could interfere with TNFα’s regulation of synaptic
plasticity. IL-1β is also important for the function of neurons
under physiological conditions. Normal concentrations of IL-
1β are essential for hippocampal long term potentiation (LTP),
however higher pathological levels (>10 ng/ml) results in the
inhibition of LTP (Katsuki et al., 1990; Bellinger et al., 1993;
Ross et al., 2003). In vivo studies are sparse, but in vitro stud-
ies have provided further evidence of a critical role of FcγR in
neuronal damage microglia co-cultured with dopaminergic neu-
rons coated with IgG from the sera of PD patients, results in
increased levels of pro-inflammatory cytokines (TNFα), reac-
tive oxygen species synthesis, and the initiation of cell death
in co-cultured neurons. The damage to neurons was shown
to be dependent on NO production, as iNOS inhibitors but
not cytokine blocking antibodies could inhibit neuronal death.
This effect was shown to be Fcγ chain-dependent as microglia
from Fcγ chain deficient mice fail to induce cytokine/ROS pro-
duction or neuronal damage (Le et al., 2001). Recently it was
shown that microglial activation in response to LPS or Aβ could
epigenetically regulate the expression of synaptic proteins, silenc-
ing neuroligin gene expression (Bie et al., 2014). The media-
tors produced by microglia which cause these effects are yet
unknown, but it is possible that antibody mediated inflammation
could also cause silencing neuroligin gene expression resulting
in synapse loss. Therefore the increased production of: TNFα,
IL-1β, NO or other inflammatory mediators by M2b polar-
ized microglia could lead to impairment of neuronal function
or exacerbation of neuronal/synapse loss in AD patients after
treatment.
We propose that FcγRs may contribute to the pathology of
neurodegenerative diseases through a number of mechanisms
(summarized in Figure 2B). It is important to consider this when
developing immunotherapies targeting CNS antigens. Targeting
Aβ leads to changes in FcγR expression on CNS effector cells,
FIGURE 2 | Mechanisms of Fc receptor mediated tissue damage in the
CNS. (A) The proposed mechanism for inflammatory tissue damage to
CNS vasculature and neurons after Anti-Aβ immunotherapy. Therapeutic
antibodies penetrate the CNS and bind to deposits of Aβ in the parenchyma
and around the blood vessels. Microglia express activating FcγR, and the
antibody-Aβ immune complexes cause cross linking and FcγR activation.
This results in a localized inflammatory response causing the vascular side
effects observed in mice and humans. Furthermore soluble inflammatory
mediators produced by this reaction may interfere with neuronal function or
induce damage. (B) There is an emerging role for Fcγ receptors in
neurodegeneration, with 3 different proposed mechanisms of Fc receptor
mediated damage to neurons. (1) Inhibitory Fcγ receptor (FcγRIIb)
expression has been detected on neurons, and FcRIIb binds Aβ with high
affinity. The ligation of Aβ by neuronal FcRIIb results in neuronal death. (2)
Autoantibodies against neurons are present in the sera of AD patients and
also observed binding to neurons. This could lead to FcγR dependant
neuronal loss through antibody dependent cellular cytotoxicity, caused by
the ligation of activating Fcγ receptors on microglia. (3) Activating FcγR
expression has been detected in certain models with neurodegenerative
disease. Ligation of IgG by neuronal Fc receptors in mice results in
neuronal loss.
if this alters the ratio of activating to inhibitory FcγR it could
exacerbate existing pathology. Furthermore immune complexes
formed in the CNS may interact with FcγR expressing cells,
including neurons. At the moment the function of FcγR on
neurons is unclear but it seems that their ligation can induce
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neuron loss. It will be important to understand the function and
consequence of neuronal FcγR activation in the development of
new immunotherapies.
THE IMPORTANCE OF FcγR IN DEVELOPING FUTURE
IMMUNOTHERAPIES FOR ALZHEIMER’S DISEASE
The role of FcγRs in the clearance of Aβ and associated side
effects
The development of anti Aβ immunotherapy has already been
reviewed elsewhere (Schenk, 2002; Brody and Holtzman, 2008;
Nitsch and Hock, 2008; Morgan, 2009; Lemere and Masliah,
2010), this section will instead focus on the side effects asso-
ciated with immunotherapy and the putative role of FcγRs in
plaque clearance. Passive immunization with anti-Aβ antibodies
reduces amyloid deposition and reverses cognitive deficiencies in
transgenic APP mice (Bard et al., 2000; DeMattos et al., 2001;
Wilcock et al., 2004b). However the reduction in parenchymal
amyloid is associated with increased deposition of Aβ around
the cerebral vasculature, and an increased incidence of cerebral
micro-hemorrhage (Wilcock et al., 2004c). Data from clinical
trials has shown that certain antibodies such as Bapineuzumab
(hIgG1 anti Aβ) are able to reduce or at least stabilize amy-
loid load in the brains of AD patients, measured by PET scan
(Rinne et al., 2010; Salloway et al., 2014). However MRI scans of
Bapineuzumab treated patients have also revealed similar vascular
side effects to APP mice. Cerebral Micro-hemorrhage (ARIA-
H) was observed at higher frequency in Bapineuzumab treated
patients than placebo, whilst vasogenic edema (ARIA-E) was
detected in 9.7% of patients treated with bapineuzumab and 0%
in the placebo group (Salloway et al., 2010). Due to these side
effects experienced by the patients, the top dose of bapineuzumab
given in phase III was abandoned, potentially contributing to
the lack of efficacy (Salloway et al., 2010). One mechanism for
the clearance of plaques by anti Aβ immunotherapy is through
FcγRmediated phagocytosis of plaques by microglia; the involve-
ment of microglia in clearance of Aβ has been reviewed (Morgan,
2009). This phagocytic clearance seems to be a double edged
sword, as the clearance of Aβ is accompanied micro-hemorrhage
and activation of microglia (Wilcock et al., 2004c). This activation
takes the form of increased expression of markers such as CD45
and MHCII, and increased transcript levels of pro inflammatory
cytokines and iNOS (Wilcock et al., 2004a,b, 2011). The proposed
mechanism for microglial mediated damage to the vasculature
and neurons is depicted in Figure 2A. Both microglial activation
and micro-hemorrhage are prevented when anti-Aβ antibodies
were deglycosylated or produced aglycosal reducing affinity for all
FcγRs (Wilcock et al., 2006; Freeman et al., 2012). These findings
have been translated into the development of Crenezumab where
the selection of an antibody with lower affinity for all FcγRs has
alleviated vascular side effects in humans (Adolfsson et al., 2012).
Are “Primed” AD brains predisposed to an exacerbated response to
immunotherapy?
Neuro-inflammation in AD is characterized by an upregula-
tion of immune regulatory receptors expressed on: microglia,
astrocytes and perivascular cells as well as increased cytokine
concentration in the brain (Peress et al., 1993; Wyss-Coray et al.,
2001). A causal role of inflammation in disease is supported by
the recent genome wide association studies identifying a number
of polymorphisms in immune receptors linked to higher risk of
late onset AD in genes such as: Complement receptor 1 (Lambert
et al., 2009), TREM2 (Guerreiro et al., 2013), HLA DR (Lambert
et al., 2013) and CD33 (Hollingworth et al., 2011). We and others
have shown that microglia, and perhaps vascular endothelial
cells, are functionally altered adopting a “primed” phenotype
with reduced threshold for innate immune activation (Lunnon
et al., 2011; Puentener et al., 2012). Stimuli such as systemic
bacterial infections can switch these cells into an aggressive
phenotype, which may explain the exaggerated cognitive decline
in AD patients with low grade systemic inflammation (Holmes
et al., 2011). We also showed that the pro-inflammatory response
is reduced in Fcγ chain deficient mice suggesting that these
receptors or their signaling pathways play a role in microglial
priming. FcγR expression in the healthy CNS is low, but altered
expression of both activating and inhibitory FcγRs as a result of
ageing and/or neuroinflammation has been observed in both ani-
mal models (Lunnon et al., 2011; Hart et al., 2012; Teeling et al.,
2012) and humans (Peress et al., 1993; Bouras et al., 2005; Cribbs
et al., 2012). As the balance of activating and inhibitory FcγRs
determines the effector function of the cell, higher expression
of immune activating tyrosine motif (ITAM) bearing receptors
in the CNS may exacerbate the response following ligation of
therapeutic antibodies coating plaques. Neurons use a number of
mechanisms to keep inflammatory response in the brain tightly
regulated, preventing damage to the CNS- these mechanisms,
include CD200 and fractalkine which have been reviewed
previously (Hoarau et al., 2011). In AD it has been shown that
these pathways are deregulated, and the inhibitory signal is
reduced. These observations may have important implications
for immunotherapy as primed microglia and/or endothelial
cells may differentially respond to therapeutic antibodies. The
loss of an inhibitory signal coupled with increased activating
FcγR expression could drive an exacerbated response to plaques
coated in antibodies. This could, at least partly, explain why
patients receiving antibodies have experienced vascular damage.
Furthermore this may lead to change in neural function as a
result of increased production of pro-inflammatory mediators
such as the cytokines IL-1β, TNFα and nitric oxide (NO) (Le
et al., 2001; Wilcock et al., 2011).
CONCLUSIONS
The clinical trials to date have shown that immunotherapy against
Aβ is able to clear plaques from the brains of AD patients.
However they have also highlighted the danger of immune acti-
vation within the CNS, which can result in damage to brain
tissue. It appears that ligation of activating FcγRs by therapeu-
tic antibodies causes damage to the vasculature of the CNS; we
propose that immunotherapy could also impair the function of
neurons through mechanisms outlined in Figure 2. We believe
that we can learn lessons from cancer immunotherapy where
the FcγR affinity of monoclonal antibodies has been optimized
by point mutations to improve efficacy. To a certain extent this
has been started by AC Immune/Genentech whose new anti-
body Crenezumab (hIgG4) has lower FcγR affinity than previous
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antibodies. It may be possible to further improve by optimizing
the relative affinity for specific FcγRs, allowing higher levels of
plaque clearance with fewer side effects. It is clear that different
FcγRs play a role in neurodegeneration by a number of mech-
anisms; however their normal function in the brain is not well
understood. To allow the production of safe and effective CNS
immunotherapies it is essential to understand the consequences
of antibody accumulation and activation of FcγRs in the CNS.
This would allow the selection the most appropriate antibody
isotypes or mutants minimizing the risk of adverse events.
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